Stimulation of angiogenesis by FGF-1 delivered through a modified fibrin scaffold.
A few studies have indicated that repeated dosing of acidic fibroblast growth factor (FGF-1) is essential to be effective in modulating the wound-healing response. However, little investigation has been done to determine the effective dosing regimen of FGF-1 or the appropriate carrier vehicle for this growth factor. The main objective of this study was to determine the effective angiogenic stimulatatory dose of FGF-1 delivered through a modified fibrin matrix, using a rabbit ear ulcer model. Specifically, the aim was to test the effects of FGF-1 on the angiogenic, fibroblastic, and epithelial responses in a wound model. Five 6-mm diameter ulcers to the depth of bare cartilage were created on each rabbit ear. Four different combinations (0.8, 8, 80, and 800 micrograms/ml) of the growth factor were examined across two periods of study. Pooled modified fibrin was used to deliver the growth factor. Histomorphometrical quantification was conducted after routine histological processing of the ulcers sites. Data analysis indicated a strong correlation between concentration and the histomorphometric response. In general, the growth factor treatments affected the healing response and exhibited a dose-dependent behavior. The addition of FGF-1 led to an increase in the angiogenic and fibroblastic responses, as well as an increase in the epithelialization rate. The preferred dose of 8 micrograms initiated a high epithelialization rate, fibroblastic, and angiogenic responses, and was the lowest dose required to initiate these responses.
Pandit
A S
AS
Department of Biomedical Engineering, University of Alabama at Birmingham 35294, USA.
Feldman
D S
DS
Caulfield
J
J
Thompson
A
A
D000818:Animals; D002417:Cattle; D004195:Disease Models, Animal; D004423:Ear / Q000473:pathology; D004848:Epithelium / Q000187:drug effects / Q000502:physiology; D005337:Fibrin / Q000502:physiology; D016220:Fibroblast Growth Factor 1 / Q000494:pharmacology*; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D008264:Macrophages / Q000378:metabolism; D008833:Microcirculation / Q000187:drug effects; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D009504:Neutrophils / Q000378:metabolism; D011817:Rabbits; D014456:Ulcer / Q000188:drug therapy / Q000473:pathology; D014945:Wound Healing / Q000187:drug effects*
D016220:Fibroblast Growth Factor 1; D005337:Fibrin